TXG
Healthcare10x Genomics, Inc.
$18.32
+$1.70 (+10.23%)
Jan 5, 2026
Price History (1Y)
Analysis
10x Genomics, Inc. is a healthcare company operating in the Health Information Services industry. With a market capitalization of $2.32 billion and annual revenue of $641.81 million, it has significant scale within its sector. The company's financial health indicates challenges in profitability, with gross margins at 68.9%, but negative operating and profit margins at -21.2% and -11.9%, respectively. Returns on equity and assets are also negative, at -10.1% and -8.4%, respectively. Its balance sheet shows a debt-to-equity ratio of 11.08, which is accompanied by $482.08 million in cash and $86.98 million in debt. The company's valuation context features an unfavorable forward P/E ratio of -44.68, as well as negative revenue growth year-over-year at -1.7%. The price-to-book ratio stands at 2.95, while the dividend yield is not applicable due to a payout ratio of 0.0% indicating no dividends have been paid out.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About 10x Genomics, Inc.
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the Americas, Europe, the Middle East, Africa, China, and the Asia Pacific. It offers Chromium platform that enables analysis of individual biological components, as well as includes microfluidic chips and related consumables, Chromium X Series, and Chromium instruments; Visium platform includes Spatial Gene Expression, HD Spatial Gene Expression, and Spatial Gene and Protein Expression assays, as well as the Visium CytAssist, an instrument designed to simplify and optimize the Visium solution workflow by facilitating the transfer of transcriptomic analytes from standard glass slides to Visium slides; and Xenium Analyzer instrument enables researchers to detect and preserve the cellular location of hundreds of RNA targets directly in a fresh frozen or FFPE tissue section. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Visit website →Key Statistics
- Market Cap
- $2.32B
- P/E Ratio
- N/A
- 52-Week High
- $20.34
- 52-Week Low
- $6.78
- Avg Volume
- 2.64M
- Beta
- 2.18
Company Info
- Industry
- Health Information Services
- Exchange
- NMS
- Country
- United States
- Employees
- 1,306